Vantia Therapeutics has announced positive results from a Phase IIa clinical trial of its lead development compound, VA106483, for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output.
29 July, 2009
Prostate cancer has overtaken lung cancer to become the most common cancer in men, affecting more than 35,000 men every year in the UK. Now, new UK research has confirmed that the cancer drug abiraterone provides a significant benefit for up to two-thirds of men with advanced and aggressive prostate cancer, according to a study published recently in the Journal of Clinical Oncology.
27 July, 2009
Scientists at The Institute of Cancer Research and The Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, have completed a Phase I clinical trial demonstrating the promise of a new type of cancer treatment.
27 July, 2009
Systemic lupus erythematosus is a chronic, life-threatening autoimmune disease. Approximately five million people worldwide suffer from various forms of lupus, including systemic lupus erythematosus, and symptoms can include extreme fatigue, painful and swollen joints, unexplained fever, skin rash, and kidney problems.
23 July, 2009
Actelion Ltd. has announced the launch of Zavesca® (miglustat), a licensed treatment available for people with Niemann-Pick type C (NP-C) disease, in the UK and Republic of Ireland.
22 July, 2009
Apthera, Inc. announced recently that it had reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the planned Phase III clinical trial of Apthera’s lead drug, NeuVax.
20 July, 2009